Mesoblast Shares Plummet Despite $260 Million Placement and FDA Approval

3 min read | January 14, 2025 11:00 AM AEDT | By Team Kalkine Media

Mesoblast Shares Plummet Despite $260 Million Placement and FDA Approval — Image source: Shutterstock

Mesoblast's Strategic Advancement

Mesoblast (ASX:MSB) recently conducted a global private placement worth $260 million, primarily targeted at existing shareholders from the US, UK, and Australia. This financial move followed the significant FDA approval of its cell therapy product, remestemcel-L, intended for treating pediatric graft-versus-host disease (GvHD). Sold at an 11% discount to the trading price, the placement marks a pivotal moment for Mesoblast, especially given the FDA's previous rejections in 2020 and 2023, which delayed the product's commercial introduction.

The raised capital will be allocated towards the clinical development and expansion of commercial manufacturing activities to meet product demand. CEO Dr. Silviu Itescu emphasized the importance of shareholder support in scaling up production for Ryoncil, the brand name for remestemcel-L. With remestemcel-L as the only FDA-approved mesenchymal stromal cell treatment for SR-aGvHD, Mesoblast plans to extend its treatment indications to both children and adults with inflammatory conditions.

Beyond remestemcel-L, Mesoblast aims to work closely with the FDA to secure approvals for other late-stage products, including Revascor, targeted at cardiovascular diseases and inflammatory pain, indicating a robust pipeline and an expansionist vision.

Atomo Diagnostics' Expanding Reach

Atomo Diagnostics (ASX:AT1) has strengthened its distribution capacity through a five-year agreement with Newfoundland Diagnostics. This deal, valued at approximately $5.44 million, underscores Atomo's commitment to expanding the availability of its HIV self-test kits. Effective immediately, Newfoundland holds exclusive distribution rights in the UK and non-exclusive rights in the EU and Colombia.

The agreement follows successful product launches in major UK retail chains such as Boots and Tesco. With Newfoundland handling distribution in additional regions like Eastern Europe and Colombia, this deal is set to significantly enhance Atomo’s market penetration and accessibility of its HIV self-test kits in growing demand areas.

The partnership also lays the groundwork for future product introductions, including Atomo's upcoming active syphilis self-test kits developed with Australian government funding.

Osteopore's Achievements in Singapore

Osteopore (ASX:OSX) has achieved a noteworthy milestone with its craniomaxillofacial and oculoplastic implants being added to the Singapore Ministry of Health's Implant Subsidy List (ISL). This inclusion is a testament to the clinical safety and cost-effectiveness of Osteopore's 3D-printed, bioresorbable implants, which promote natural tissue regeneration and bone healing.

The ISL provides subsidies to implants that meet stringent safety and effectiveness criteria, encouraging their use for improved patient outcomes. CEO Dr. Yujing Lim highlighted the recognition as a vital step in offering advanced, affordable regenerative treatments in Singapore, aiming to enhance accessibility and patient recovery experiences.

These developments indicate Osteopore's ongoing commitment to delivering innovative healthcare solutions, leveraging cutting-edge technology to facilitate the natural recovery process.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.